Inhaled nitric oxide drug products developer GeNO has received four additional US patents on its proprietary inhaled nitric oxide (NO) generation chemistry and delivery technology, bringing the total number of US patents to sixteen.
The patent number 8,211,368 will describe the conversion of nitrogen dioxide (NO2) to nitric oxide (NO) where the NO2 is stored as a liquid in a permeation tube.
The patent number 8,221,800 will describe the use of a nitrite salt to release NO within the GeNO NO delivery system while patent number 8,226,916 relates to the conversion of a liquid NO2 to NO using an antioxidant.
The US patent number 8,246,725 describes a method of making a device that converts NO2 to NO.
GeNO LLC president and founder David Fine said the four new patents follow FDA clearance earlier the year of GeNO's 510(k) premarket notification to begin commercialization of acute inhaled nitric oxide (NO) administration apparatus, as well as orphan drug designation for its nitric oxide (delivered via the GeNOsyl MVG-2000 delivery system) for the treatment of Persistent Pulmonary Hypertension in Newborns (PPHN).
"These four new patents, together with GeNO's existing patent portfolio, position GeNO to be a major player in the inhaled NO drug market," Fine added.
GeNO has been developing a stand-alone gas cylinder system, a ventilator-based platform and a pocket-sized ambulatory system, which are all nitric oxide delivery platforms.
GeNO's nitric oxide gas is used to treat pulmonary and cardiac diseases.
